SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Sandra Phillips, Shilpa Chokshi, Udayan Chatterji, Antonio Riva, Michael Bobardt, Roger Williams, Philippe Gallay, Nikolai V. Naoumov, Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production, Gastroenterology, 2015, 148, 2, 403

    CrossRef

  2. 2
    N. Désiré, Y. Ngo, J.-F. Franetich, L. Dembele, D. Mazier, J.-C. Vaillant, T. Poynard, V. Thibault, Definition of an HBsAg to DNA international unit conversion factor by enrichment of circulating hepatitis B virus forms, Journal of Viral Hepatitis, 2015, 22, 8
  3. 3
    Fatemeh Bakhshizadeh, Soheila Hekmat, Maryam Keshvari, Seyed Moayed Alavian, Ehsan Mostafavi, Hossein Keivani, Amin Doosti, Fatemeh Motevalli, Bita Behnava, Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleoside-Analogue Naive Iranian Patients Treated for Chronic Hepatitis B, Hepatitis Monthly, 2015, 15, 5

    CrossRef

  4. 4
    I. Carey, M. Bruce, M. Horner, Y. Zen, L. D'Antiga, S. Bansal, D. Vergani, G. Mieli-Vergani, HBsAg plasma level kinetics: a new role for an old marker as a therapy response predictor in vertically infected children on combination therapy, Journal of Viral Hepatitis, 2015, 22, 4
  5. 5
    Michelle Martinot-Peignoux, Tarik Asselah, Patrick Marcellin, HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients, Liver International, 2015, 35,
  6. 6
    Tetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, Taito Fukushima, Yusuke Kawamura, Hitomi Sezaki, Norio Akuta, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada, HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy, Liver International, 2015, 35, 4
  7. 7
    Margo J. H. van Campenhout, Harry L. A. Janssen, How to achieve immune control in chronic hepatitis B?, Hepatology International, 2015, 9, 1, 9

    CrossRef

  8. 8
    Barbara Rehermann, Antonio Bertoletti, Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections, Hepatology, 2015, 61, 2
  9. 9
    Fabien Zoulim, Giampiero Carosi, Susan Greenbloom, Wlodzimierz Mazur, Tuan Nguyen, Lennox Jeffers, Maurizia Brunetto, Song Yu, Cyril Llamoso, Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study, Journal of Hepatology, 2015, 62, 1, 56

    CrossRef

  10. 10
    Patrick Marcellin, Karsten Wursthorn, Heiner Wedemeyer, Wan-Long Chuang, George Lau, Claudio Avila, Cheng-Yuan Peng, Edward Gane, Seng Gee Lim, Hugo Fainboim, Graham R. Foster, Rifaat Safadi, Mario Rizzetto, Michael Manns, Weibin Bao, Aldo Trylesinski, Nikolai Naoumov, Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy, Journal of Hepatology, 2015, 62, 1, 41

    CrossRef

  11. 11
    Nina Nikolova, Deian Jelev, Krasimir Antonov, Lyudmila Mateva, Zahariy Krastev, The decrease of HBsAg during nucleos(t)ide analogues (NUC) therapy in Bulgarian patients, Biotechnology & Biotechnological Equipment, 2015, 29, 4, 746

    CrossRef

  12. 12
    Miriam Romero, Antonio Madejón, Javier García-Samaniego, ¿Es útil la cuantificación de los niveles del HBsAg en el control del paciente con infección crónica por el virus de la hepatitisB?, Gastroenterología y Hepatología, 2014, 37, 6, 350

    CrossRef

  13. 13
    Toshihiro Kawaguchi, Ichiro Miyajima, Ryohei Kaji, Sigenari Sakakibara, Atsusi Mori, Tomoyuki Nakane, Kensuke Miyahara, Ryuichiro Maekawa, Yoichi Yano, Takuji Torimura, Michio Sata, A case of HBsAg seroclearance by readministration of lamivudine and adefovir dipivoxil in patient with liver cirrhosis due to hepatitis B virus infection, Kanzo, 2014, 55, 11, 706

    CrossRef

  14. 14
    Chia-Chi Wang, Tai-Chung Tseng, Pin-Chao Wang, Hans Hsienhong Lin, Jia-Horng Kao, Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients, Journal of the Formosan Medical Association, 2014, 113, 11, 786

    CrossRef

  15. 15
    Jong Eun Yeon, Clinical Significance of Hepatitis B Surface Antigen Quantification in Chronic Hepatitis B, The Korean Journal of Gastroenterology, 2014, 63, 6, 335

    CrossRef

  16. 16
    Ming-Chao Tsai, Hsien-Chung Yu, Chao-Hung Hung, Chuan-Mo Lee, King-Wah Chiu, Ming-Tzung Lin, Po-Lin Tseng, Kuo-Chin Chang, Yi-Hao Yen, Chien-Hung Chen, Tsung-Hui Hu, Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis, Journal of Gastroenterology and Hepatology, 2014, 29, 3
  17. You have free access to this content17
    Maria Buti, HBeAg-positive chronic hepatitis B: Why do I treat my patients with Nucleos(t)ide Analogs?, Liver International, 2014, 34,
  18. You have free access to this content18
    Michelle Martinot-Peignoux, Martine Lapalus, Tarik Asselah, Patrick Marcellin, HBsAg quantification: useful for monitoring natural history and treatment outcome, Liver International, 2014, 34,
  19. 19
    G.-A. Kim, Y.-S. Lim, J. An, D. Lee, J. H. Shim, K. M. Kim, H. C. Lee, Y.-H. Chung, Y. S. Lee, D. J. Suh, HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability, Gut, 2014, 63, 8, 1325

    CrossRef

  20. 20
    Emilia Hadziyannis, Stephanos J Hadziyannis, Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility, Expert Review of Gastroenterology & Hepatology, 2014, 8, 2, 185

    CrossRef

  21. 21
    Andrzej Taranta, Bui Tien Sy, Behrend Johan Zacher, Magdalena Rogalska-Taranta, Michael Peter Manns, Claus Thomas Bock, Karsten Wursthorn, Hepatitis B virus DNA quantification with the three-in-one (3io) method allows accurate single-step differentiation of total HBV DNA and cccDNA in biopsy-size liver samples, Journal of Clinical Virology, 2014, 60, 4, 354

    CrossRef

  22. 22
    Catherine W. Cai, Elena Lomonosova, Eileen A. Moran, Xiaohong Cheng, Kunjan B. Patel, Fabrice Bailly, Philippe Cotelle, Marvin J. Meyers, John E. Tavis, Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity, Antiviral Research, 2014, 108, 48

    CrossRef

  23. 23
    Lena Allweiss, Tassilo Volz, Marc Lütgehetmann, Katja Giersch, Till Bornscheuer, Ansgar W. Lohse, Joerg Petersen, Han Ma, Klaus Klumpp, Simon P. Fletcher, Maura Dandri, Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration, Journal of Hepatology, 2014, 60, 3, 500

    CrossRef

  24. 24
    Patrick Marcellin, Maria Buti, Zahari Krastev, Robert A. de Man, Stefan Zeuzem, Lillian Lou, Anuj Gaggar, John F. Flaherty, Benedetta Massetto, Lanjia Lin, Phillip Dinh, G. Mani Subramanian, John G. McHutchison, Robert Flisiak, Selim Gurel, Geoffrey M. Dusheiko, E. Jenny Heathcote, Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate, Journal of Hepatology, 2014, 61, 6, 1228

    CrossRef

  25. 25
    Yuecheng Yu, Jinlin Hou, Masao Omata, Yue Wang, Lanjuan Li, Loss of HBsAg and antiviral treatment: from basics to clinical significance, Hepatology International, 2014, 8, 1, 39

    CrossRef

  26. 26
    F. Cao, S. Jones, W. Li, X. Cheng, Y. Hu, J. Hu, J. E. Tavis, Sequences in the terminal protein and reverse transcriptase domains of the hepatitis B virus polymerase contribute to RNA binding and encapsidation, Journal of Viral Hepatitis, 2014, 21, 12
  27. 27
    R. Strassl, T. Reiberger, C. Honsig, B. A. Payer, M. Mandorfer, K. Grabmeier-Pfistershammer, A. Rieger, M. Kundi, P. Grundtner, M. Peck-Radosavljevic, T. Popow-Kraupp, Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients, Journal of Viral Hepatitis, 2014, 21, 7
  28. 28
    Wei-Chih Su, Tsung-Cheng Hsieh, Tsai-Yuan Hsieh, Kuo-Chih Tseng, Cheng-Yuan Peng, Chih-Lin Lin, Tung-Hung Su, Tsung-Hsien Hsiao, Tai-Chung Tseng, Hans Hsienhong Lin, Chia-Chi Wang, Jia-Horng Kao, Younger age and female sex predict a better therapeutic response in HBeAg-positive chronic hepatitis B patients to entecavir therapy, Advances in Digestive Medicine, 2014, 1, 4, 112

    CrossRef

  29. 29
    Soon Sun Kim, Dami Lee, Myoung Hee Lee, Jae Youn Cheong, Sung Won Cho, Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B, Hepatology Research, 2013, 43, 3
  30. 30
    Stephen E. Congly, Philip Wong, Said A. Al-Busafi, Karen Doucette, Scott K. Fung, Peter Ghali, Kevin Fonseca, Robert P. Myers, Carla Osiowy, Carla S. Coffin, Characterization of hepatitis B virus genotypes and quantitative hepatitis B surface antigen titres in North American tertiary referral liver centres, Liver International, 2013, 33, 9
  31. 31
    Timothy M. Block, Robert Gish, Haitao Guo, Anand Mehta, Andrea Cuconati, W. Thomas London, Ju-Tao Guo, Chronic hepatitis B: What should be the goal for new therapies?, Antiviral Research, 2013, 98, 1, 27

    CrossRef

  32. 32
    Tetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, Yuya Seko, Yusuke Kawamura, Hitomi Sezaki, Norio Akuta, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada, Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study, Journal of Gastroenterology, 2013, 48, 8, 930

    CrossRef

  33. 33
    Pin-Nan Cheng, Hung-Wen Tsai, Yen-Cheng Chiu, Cheng-Hsun Ho, I-Chin Wu, Ting-Tsung Chang, Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B, Journal of Clinical Virology, 2013, 57, 4, 323

    CrossRef

  34. 34
    Tai-Chung Tseng, Jia-Horng Kao, Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog, Journal of Gastroenterology, 2013, 48, 1, 13

    CrossRef

  35. 35
    Tatiana Dupinay, Tarik Gheit, Pierre Roques, Lucyna Cova, Philippe Chevallier-Queyron, Shin-i Tasahsu, Roger Grand, François Simon, Geneviève Cordier, Lahcen Wakrim, Soumaya Benjelloun, Christian Trépo, Isabelle Chemin, Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from mauritius island, Hepatology, 2013, 58, 5
  36. You have free access to this content36
    Y. Wang, S. Thongsawat, E. J. Gane, Y.-F. Liaw, J. Jia, J. Hou, H. L. Y. Chan, G. Papatheodoridis, M. Wan, J. Niu, W. Bao, A. Trylesinski, N. V. Naoumov, Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B, Journal of Viral Hepatitis, 2013, 20, 4
  37. 37
    Michelle Martinot-Peignoux, Tarik Asselah, Patrick Marcellin, HBsAg Quantification to Predict Natural History and Treatment Outcome in Chronic Hepatitis B Patients, Clinics in Liver Disease, 2013, 17, 3, 399

    CrossRef

  38. 38
    Chih-Lin Lin, Jia-Horng Kao, Hepatitis B viral factors and treatment responses in chronic hepatitis B, Journal of the Formosan Medical Association, 2013, 112, 6, 302

    CrossRef

  39. 39
    H. Yotsuyanagi, K. Ito, N. Yamada, H. Takahashi, C. Okuse, K. Yasuda, M. Suzuki, K. Moriya, M. Mizokami, Y. Miyakawa, K. Koike, High Levels of Hepatitis B Virus After the Onset of Disease Lead to Chronic Infection in Patients With Acute Hepatitis B, Clinical Infectious Diseases, 2013, 57, 7, 935

    CrossRef

  40. 40
    John E Tavis, Adam J Gehring, Yuan Hu, How further suppression of virus replication could improve current HBV treatment, Expert Review of Anti-infective Therapy, 2013, 11, 8, 755

    CrossRef

  41. 41
    Lucio Boglione, Antonio D'Avolio, Giuseppe Cariti, Gabriella Gregori, Elisa Burdino, Lorena Baietto, Jessica Cusato, Valeria Ghisetti, Francesco G. De Rosa, Giovanni Di Perri, Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D, Liver International, 2013, 33, 4
  42. 42
    Stéphane Chevaliez, Christophe Hézode, Stéphane Bahrami, Marion Grare, Jean-Michel Pawlotsky, Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely, Journal of Hepatology, 2013, 58, 4, 676

    CrossRef

  43. 43
    Etienne M. Sokal, Massimiliano Paganelli, Stefan Wirth, Piotr Socha, Pietro Vajro, Florence Lacaille, Deirdre Kelly, Giorgina Mieli-Vergani, Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines, Journal of Hepatology, 2013, 59, 4, 814

    CrossRef

  44. 44
    Wai-Kay Seto, Kevin Liu, Danny Ka-Ho Wong, James Fung, Fung-Yu Huang, Ivan Fan-Ngai Hung, Ching-Lung Lai, Man-Fung Yuen, Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment, Journal of Hepatology, 2013, 59, 4, 709

    CrossRef

  45. 45
    Hsien-Chung Yu, Kung-Hung Lin, Ping-I Hsu, Feng-Woei Tsay, Huay-Min Wang, Tzung-Jiun Tsai, Kwok-Hung Lai, Real-World Application of the Roadmap Model in Chronic Hepatitis B Patients with Telbivudine Therapy, Clinical Therapeutics, 2013, 35, 9, 1386

    CrossRef

  46. 46
    Danny Ka-Ho Wong, Wai-Kay Seto, James Fung, Philip Ip, Fung-Yu Huang, Ching-Lung Lai, Man-Fung Yuen, Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency, Clinical Gastroenterology and Hepatology, 2013, 11, 8, 1004

    CrossRef

  47. 47
    Yun-hao Xun, Guo-qing Zang, Jian-chun Guo, Xiu-li Yu, Hong Liu, Jing Xiang, Jing Liu, Jun-ping Shi, Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers, Journal of Gastroenterology and Hepatology, 2013, 28, 11
  48. 48
    H. You, J. Jia, Telbivudine treatment in chronic hepatitis B: experience from China, Journal of Viral Hepatitis, 2013, 20,
  49. 49
    G.-Q. Wang, Y.-P. Ding, Y.-H. Dong, Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients, Journal of Viral Hepatitis, 2013, 20,
  50. 50
    Kate Childs, Deepak Joshi, Ruth Byrne, Matthew Bruce, Ivana Carey, Kosh Agarwal, Chris Taylor, Tenofovir-based combination therapy for HIV/HBV co-infection, AIDS, 2013, 27, 9, 1443

    CrossRef

  51. You have free access to this content51
    Michelle Martinot-Peignoux, Martine Lapalus, Tarik Asselah, Patrick Marcellin, The role of HBsAg quantification for monitoring natural history and treatment outcome, Liver International, 2013, 33,
  52. 52
    Yuan Hu, Xiaohong Cheng, Feng Cao, Ailong Huang, John E. Tavis, β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity, Antiviral Research, 2013, 99, 3, 221

    CrossRef

  53. 53
    Swastik Agrawal, Radha K Dhiman, Answers to Multiple Choice Questions, Journal of Clinical and Experimental Hepatology, 2012, 2, 2, 200

    CrossRef

  54. 54
    Yun-Fan Liaw, Jia-Horng Kao, Teerha Piratvisuth, Henry Lik Yuen Chan, Rong-Nan Chien, Chun-Jen Liu, Ed Gane, Stephen Locarnini, Seng-Gee Lim, Kwang-Hyub Han, Deepak Amarapurkar, Graham Cooksley, Wasim Jafri, Rosmawati Mohamed, Jin-Lin Hou, Wan-Long Chuang, Laurentius A. Lesmana, Jose D. Sollano, Dong-Jin Suh, Masao Omata, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update, Hepatology International, 2012, 6, 3, 531

    CrossRef

  55. 55
    Maria Buti, Francisco Rodríguez Frías, Rafael Esteban, Cuantificación del antígeno de superficie del virus de la hepatitis B: implicaciones clínicas, Medicina Clínica, 2012, 138, 11, 483

    CrossRef

  56. 56
    Yi–Cheng Chen, Wen–Juei Jeng, Chia–Ming Chu, Yun–Fan Liaw, Decreasing Levels of HBsAg Predict HBsAg Seroclearance in Patients With Inactive Chronic Hepatitis B Virus Infection, Clinical Gastroenterology and Hepatology, 2012, 10, 3, 297

    CrossRef

  57. 57
    EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection, Journal of Hepatology, 2012, 57, 1, 167

    CrossRef

  58. 58
    Chao Wei Hsu, You Chen Chao, Chuan Mo Lee, Ting Tsung Chang, Yi Cheng Chen, Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24, BMC Gastroenterology, 2012, 12, 1, 178

    CrossRef

  59. 59
    Avnish K Seth, HBsAg Quantification in Clinical Practice, Journal of Clinical and Experimental Hepatology, 2012, 2, 1, 75

    CrossRef

  60. 60
    R. Zoutendijk, H. L. Zaaijer, T. E. M. S. de Vries-Sluijs, J. G. P. Reijnders, J. W. Mulder, F. P. Kroon, C. Richter, A. A. van der Eijk, M. J. Sonneveld, B. E. Hansen, R. A. de Man, M. E. van der Ende, H. L. A. Janssen, Hepatitis B Surface Antigen Declines and Clearance During Long-Term Tenofovir Therapy in Patients Coinfected With HBV and HIV, Journal of Infectious Diseases, 2012, 206, 6, 974

    CrossRef

  61. 61
    Eduard Arendt, Jerzy Jaroszewicz, Jürgen Rockstroh, Dirk Meyer-Olson, Behrend J. Zacher, Ingmar Mederacke, Michael P. Manns, Heiner Wedemeyer, Markus Cornberg, Karsten Wursthorn, Improved Immune Status Corresponds with Long-Term Decline of Quantitative Serum Hepatitis B Surface Antigen in HBV/HIV Co-infected Patients, Viral Immunology, 2012, 25, 6, 442

    CrossRef

  62. 62
    Sudeep Tanwar, Geoffrey Dusheiko, Is There Any Value to Hepatitis B Virus Genotype Analysis?, Current Gastroenterology Reports, 2012, 14, 1, 37

    CrossRef

  63. 63
    Sarah Maylin, Anders Boyd, Fabien Lavocat, Joel Gozlan, Caroline Lascoux-Combe, Patrick Miailhes, Ludovic Lassel, Constance Delaugerre, Pierre-Marie Girard, Fabien Zoulim, Karine Lacombe, Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV–hepatitis B virus-infected patients, AIDS, 2012, 26, 8, 939

    CrossRef

  64. 64
    Stéphane Chevaliez, Christophe Rodriguez, Jean–Michel Pawlotsky, New Virologic Tools for Management of Chronic Hepatitis B and C, Gastroenterology, 2012, 142, 6, 1303

    CrossRef

  65. 65
    J. W. Shin, S. W. Jung, B. R. Park, C. J. Kim, J. B. Eum, B. G. Kim, I. D. Jeong, S.-J. Bang, S.-H. Lee, S. R. Kim, N. H. Park, Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels, Journal of Viral Hepatitis, 2012, 19, 10
  66. 66
    Sarah Maylin, Quantification de l’AgHBs : nouvel outil virologique pour la prise en charge de l’hépatite B chronique, Revue Francophone des Laboratoires, 2012, 2012, 447, 33

    CrossRef

  67. 67
    E. Bouthry, A. Pivert, A. Ducancelle, F. Lunel-Fabiani, Quantification de l’antigène HBs : intérêts et limites dans le suivi des patients infectés par le virus de l’hépatite B, Immuno-analyse & Biologie Spécialisée, 2012, 27, 6, 332

    CrossRef

  68. 68
    I. Mederacke, C. Yurdaydin, A. Großhennig, A. Erhardt, Y. Cakaloglu, K. Yalcin, S. Gurel, S. Zeuzem, K. Zachou, C. Chatzikyrkou, H. Bozkaya, G. N. Dalekos, M. P. Manns, H. Wedemeyer, Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection, Journal of Viral Hepatitis, 2012, 19, 6
  69. 69
    Peter Karayiannis, Serum Hepatitis B Surface Antigen Levels and Their Utility as a Predictor of Sustained Virological Response After Antiviral Treatment, Hepatitis Monthly, 2012, 12, 7, 420

    CrossRef

  70. 70
    Yun-Fan Liaw, Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review, Hepatology, 2011, 54, 2
  71. 71
    Yun-Fan Liaw, Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review, Hepatology, 2011, 53, 6
  72. 72
    Chul Ju Han, Could HBsAg Quantification Predict Sustained Response Following Antiviral Therapy for Chronic Hepatitis B?, The Korean Journal of Gastroenterology, 2011, 58, 6, 364

    CrossRef

  73. 73
    I. Mederacke, M. Meier, J. B. Luth, H. Schmidt-Gurtler, R. Raupach, R. Horn-Wichmann, K. Wursthorn, A. Potthoff, G. Colucci, M. P. Manns, H. Wedemeyer, H. L. Tillmann, Different kinetics of HBV and HCV during haemodialysis and absence of seronegative viral hepatitis in patients with end-stage renal disease, Nephrology Dialysis Transplantation, 2011, 26, 8, 2648

    CrossRef

  74. 74
    Robert Perrillo, Editorial: Measurement of HBsAg Concentration During Antiviral Therapy of Hepatitis B: Who, When, and Why, The American Journal of Gastroenterology, 2011, 106, 10, 1774

    CrossRef

  75. 75
    W. Graham Cooksley, Hepatitis B Genotypes: Role of Testing in Clinical Practice, Current Hepatitis Reports, 2011, 10, 2, 79

    CrossRef

  76. 76
    M. J. Sonneveld, R. Zoutendijk, H. L. A. Janssen, Hepatitis B surface antigen monitoring and management of chronic hepatitis B, Journal of Viral Hepatitis, 2011, 18, 7
  77. 77
    Henry Lik-Yuen Chan, Alex Thompson, Michelle Martinot-Peignoux, Teerha Piratvisuth, Markus Cornberg, Maurizia Rossana Brunetto, Hans L. Tillmann, Jia-Horng Kao, Ji-Dong Jia, Heiner Wedemeyer, Stephen Locarnini, Harry L.A. Janssen, Patrick Marcellin, Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report, Journal of Hepatology, 2011, 55, 5, 1121

    CrossRef

  78. 78
    Beom Kyung Kim, Kwang-Hyub Han, Sang Hoon Ahn, Hepatitis B Virus Serology to Predict Antiviral Response in Chronic Hepatitis B, Digestion, 2011, 84, s1, 29

    CrossRef

  79. 79
    Yoo-Kyung Cho, Byung-Cheol Song, New Insight for HBV DNA and HBsAg Quantitation during Antiviral Therapy in Patients with Chronic Hepatitis B, The Korean Journal of Gastroenterology, 2011, 57, 3, 144

    CrossRef

  80. 80
    Y. Liang, J. Jiang, M. Su, Z. Liu, W. Guo, X. Huang, R. Xie, S. Ge, J. Hu, Z. Jiang, M. Zhu, V. W.-S. Wong, H. L.-Y. Chan, Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy, Alimentary Pharmacology & Therapeutics, 2011, 34, 3
  81. 81
    Joon Chang Song, Bo Young Min, Jin-Wook Kim, Jong Yeop Kim, Yeo Myeong Kim, Cheol Min Shin, Sang Hyub Lee, Jin-Hyeok Hwang, Sook-Hyang Jeong, Nayoung Kim, Dong Ho Lee, Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B, The Korean Journal of Hepatology, 2011, 17, 4, 268

    CrossRef

  82. 82
    Chih-Lin Lin, Jia-Horng Kao, Recent advances in the treatment of chronic hepatitis B, Expert Opinion on Pharmacotherapy, 2011, 12, 13, 2025

    CrossRef

  83. 83
    R. Zoutendijk, B. E. Hansen, A. J. van Vuuren, C. A. B. Boucher, H. L. A. Janssen, Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss, Journal of Infectious Diseases, 2011, 204, 3, 415

    CrossRef

  84. 84
    Hejun Yuan, William M Lee, Update of chronic hepatitis B, Current Opinion in Gastroenterology, 2011, 27, 3, 217

    CrossRef